Evaluation of the Oncomine™️ Comprehensive Assay Plus for genomic profiling including HRD assessment

12/10/2024

December 10, 2024 - 5:00 PM CET

Evaluation of the Oncomine Comprehensive Assay Plus for comprehensive genomic profiling including homologous recombination deficiency assessment.

Precision oncology research continues to explore the utility of targeted therapies and immunotherapies. As we gain a deeper understanding of the molecular mechanisms of tumor biology, comprehensive genomic profiling (CGP) is critical to help drive insights into advancing the future of personalized medicine. In this webinar, learn how the Ion Torrent™ Oncomine™ Comprehensive Assay Plus, an amplicon-based next-generation sequencing (NGS) assay, can be used to simultaneously analyze a broad range of biomarkers, including homologous recombination deficiency (HRD), in one test to maximize insights into the underlying oncogenic drivers in timely manner.

Webinar Learning Objectives

Factors to consider when evaluating NGS technologies for CGP
The relevance of CGP to detect variants across tumor sample types
The importance of genomic signatures like HRD testing in ovarian cancer research samples and how it can be measured

^{For Research Use Only. Not for use in diagnostic procedures.}

Email*

Choose a password*

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the Retina field I want to stay up to date with the Infectious Diseases field I want to stay up to date with the Pathologist Educator field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.